All lobbying filings

WHITMER & WORRALL, LLC

Lobbying for CAMPAIGN FOR SUSTAINABLE DRUG PRICING (CSRXP) · Coalition to promote lowering prescription drug prices.

Filing 3rd Quarter - Report

Reporting period

3rd Quarter 2025

July 1 - Sep 30 · Posted Oct 20, 2025

Income

$50,000.00

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 2

MARTIN WHITMER

Previously held: Deputy CoS-USDOT
ERIK KOMENDANT

Previously held: Legislative Correspondent, Rep. Zoe Lofgren (CA); Legislative Director, Rep. Jason Altmire (PA); Policy Director, Blue Dog Coalition

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when.

Bills named in this filing 24

HR 3789
DTC Act of 2025
S 229
DTC Act of 2025
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
S 1041
Affordable Prescriptions for Patients Act
HR 4570
Interagency Patent Coordination and Improvement Act of 2025
S 1097
Interagency Patent Coordination and Improvement Act of 2025
S 2658
Medication Affordability and Patent Integrity Act
S 1096
Preserve Access to Affordable Generics and Biosimilars Act
HR 3160
PREVAIL Act
S 1533
A bill to amend title 38, United States Code, to make permanent and codify the pilot program for use of contract physic…
S 1546
Patent Eligibility Restoration Act of 2025
HR 3152
Patent Eligibility Restoration Act of 2025
S 43
Skinny Labels, Big Savings Act
HR 5526
Biosimilar Red Tape Elimination Act
S 1954
Biosimilar Red Tape Elimination Act
S 1785
No Handouts for Drug Advertisements Act
HR 3010
No Handouts for Drug Advertisements Act
S 1040
Drug Competition Enhancement Act
HR 3269
ETHIC Act
S 2276
ETHIC Act
S 1095
Stop STALLING Act
S 1032
Major Richard Star Act
HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
S 2630
Saving NSF’s Workforce Act

Lobbying activity 3

Medicare/Medicaid

Issues related to prescription drug prices. Fair Accountability and Innovative Research Drug Pricing Act. H.R. 3789/S.229 DTC Act of 2025. Issues related to H.R. 1, One Big Beautiful Bill Act.

Patent abuse issues. S. 1041 Affordable Prescriptions for Patients Act of 2025. H.R. 4570/S. 1097 Interagency Patent Coordination Act. S. 2658, Medication Affordability and Patent Integrity Act. S. 1096 Preserve Access to Affordable Generics and Biosimilars Act. H.R. 3160 & S. 1533, the PREVAIL Act. S. 1546 & H.R. 3152, the Patent Eligibility Restoration Act of 2025. S.43 Skinny Labels, Big Savings Act. H.R. 5526/S. 1954, the Biosimilar Red Tape Elimination Act. S. 1785 & H.R. 3010, the No Handouts for Drug Advertisements Act. S.1040 Drug Competition Enhancement Act. H.R. 3269 /S. 2276, Eliminating Thickets to Increase Competition (ETHIC) Act.

Pharmacy

Issues related to prescription drug pricing. Biosimilar Red Tape Elimination Act. S. 1095 Stop Significant and Time-Wasting Abuse Limiting Legitimate Innovation of New Generics Act. Ensuring Timely Access to Generics Act. S. 1032/H.R. 1843 Increasing Transparency in Generic Drug Applications Act. S. 2630, Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.